Palisade Bio (PALI) Accumulated Depreciation & Amortization (2011 - 2020)
Palisade Bio (PALI) reported Accumulated Depreciation & Amortization of $910956.0 for Q4 2020, down 4.15% year-over-year from $950417.0 in Q1 2020, and down 4.15% on a QoQ basis from $950417.0 in Q4 2019.
Palisade Bio (PALI) has 10 years of Accumulated Depreciation & Amortization data on file, last reported at $910956.0 in Q4 2020.
- Quarterly Accumulated Depreciation & Amortization fell 4.15% year-over-year to $910956.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $910956.0 (down 4.15% YoY) and the FY2020 annual result came in at $910956.0, down 4.15% from the prior year.
- Accumulated Depreciation & Amortization fell to $910956.0 in Q4 2020 per PALI's latest filing, from $950417.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $950417.0 in Q4 2019 and bottomed at $724771.0 in Q4 2016.
- The 5-year median for Accumulated Depreciation & Amortization is $902260.0 (2018), against an average of $862065.8.
- The widest annual swing landed in 2016, when Accumulated Depreciation & Amortization grew 15.31%; it then slipped 4.15% in 2020.
- Tracing PALI's Accumulated Depreciation & Amortization over 5 years: stood at $724771.0 in 2016, then increased by 13.4% to $821925.0 in 2017, then gained by 9.77% to $902260.0 in 2018, then gained by 5.34% to $950417.0 in 2019, then fell by 4.15% to $910956.0 in 2020.
- Per Business Quant, the three latest PALI Accumulated Depreciation & Amortization figures stand at $910956.0 (Q4 2020), $950417.0 (Q4 2019), and $902260.0 (Q4 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 910,956.00 |
| Dec 31, 2020 | 910,956.00 |
| Dec 31, 2019 | 950,417.00 |
| Dec 31, 2019 | 950,417.00 |
| Dec 31, 2018 | 902,260.00 |
| Dec 31, 2018 | 902,260.00 |
| Dec 31, 2017 | 821,925.00 |
| Dec 31, 2017 | 821,925.00 |
| Dec 31, 2016 | 724,771.00 |
| Dec 31, 2016 | 724,771.00 |
| Dec 31, 2015 | 628,551.00 |
| Dec 31, 2015 | 628,551.00 |
| Dec 31, 2014 | 483,232.00 |
| Dec 31, 2014 | 483,232.00 |
| Dec 31, 2013 | 346,134.00 |
| Dec 31, 2013 | 346,134.00 |
| Dec 31, 2012 | 423,644.00 |
| Dec 31, 2012 | 423,644.00 |
| Dec 31, 2011 | 322,628.00 |
| Dec 31, 2011 | 322,628.00 |